4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7% – Here’s What Happened

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) fell 3.7% on Friday . The company traded as low as $15.48 and last traded at $15.50. Approximately 533,967 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 825,387 shares. The stock had previously closed at $16.10.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on FDMT shares. The Goldman Sachs Group reiterated a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday. Finally, Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.62.

4D Molecular Therapeutics Trading Down 3.9%

The business’s 50-day moving average is $11.47 and its 200 day moving average is $10.08. The firm has a market capitalization of $854.62 million, a P/E ratio of -5.88 and a beta of 2.73. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. As a group, analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider David Kirn sold 114,746 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the transaction, the insider owned 942,485 shares of the company’s stock, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 200,496 shares of company stock worth $2,240,244. Corporate insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at $39,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics during the third quarter worth about $41,000. AQR Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics in the first quarter valued at approximately $46,000. Daiwa Securities Group Inc. raised its holdings in 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after buying an additional 6,186 shares during the last quarter. Finally, Rangeley Capital LLC bought a new position in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $48,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.